DOCSLIB.ORG

| Hao Wanathi Movie Plena Matuma Wa Mt

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
| Hao Wanathi Movie Plena Matuma Wa Mt |HAO WANATHI MOVIEUS009943500B2 PLENA MATUMA WA MT (12 ) United States Patent ( 10 ) Patent No. : US 9 ,943 , 500 B2 Page (45 ) Date of Patent: Apr . 17 , 2018 ( 54 ) METHODS OF TREATING TOPICAL A61K 9 /0046 ; A61K 9 / 06 ; A61K 47 /10 ; MICROBIAL INFECTIONS A61K 47 / 14 ; A61K 47 / 44 ; A61K 9 /0048 ; A61K 47/ 06 ; A61L 15 / 46 ; A61L ( 71 ) Applicant: LUODA PHARMA PTY LIMITED , 2300 /404 ; A61L 26 /0066 Caringbah ( AU ) See application file for complete search history . (72 ) Inventor : Stephen Page , Newtown ( AU ) ( 56 ) References Cited (73 ) Assignee : Luoda Pharma Pty Ltd , Caringbah U . S . PATENT DOCUMENTS (AU ) 3 ,873 , 693 A 3 / 1975 Meyers et al . 3 , 920 ,847 A * 11/ 1975 Chalaust .. .. A61K 9 /0014 Subject to any disclaimer, the term of this 514 / 512 ( * ) Notice : 4 ,772 , 470 A * 9 / 1988 Inoue .. .. .. .. .. A61K 9 / 006 patent is extended or adjusted under 35 424 / 435 U . S . C . 154 ( b ) by 0 days . 2005/ 0187199 Al * 8 /2005 Peyman .. .. .. A61K 8 / 36 514 / 154 ( 21) Appl. No .: 14 / 766 , 232 FOREIGN PATENT DOCUMENTS ( 22 ) PCT Filed : FebD . 10 , 2014 EP 0294538 A2 12 / 1988 WO WO - 2003/ 088965 A1 10 / 2003 ( 86 ) PCT No . : PCT/ AU2014 /000101 WO WO - 2006 /081327 A2 8 /2006 $ 371 ( c ) ( 1 ) , WO WO - 2008 /075207 A2 6 / 2008 ( 2 ) Date : Aug. 6 , 2015 OTHER PUBLICATIONS (87 ) PCT Pub . No .: W02014 / 121342 Weese et. al. , Veterinary Microbiology , 2010 , Elsevier, vol. 140 , pp . PCT Pub . Date : Aug . 14 , 2014 418 - 429 . * Brindle , Encyclopedia of Chemical Technology . Polyether antibi otics, Nov . 2013 , Wiley , Abstract and pp . 1 - 30 . * (65 ) Prior Publication Data Huczynski et. al ., Journal of Molecular Structure , 2008 , Elsevier , US 2016 / 0000748 A1 Jan . 7 , 2016 vol. 891 , pp . 481 -490 . * Chen et . al. , Journal of Medicinal Chemistry , 2001, American Foreign Application Priority Data Chemical Society , vol. 44 , pp . 2374 - 2377 . * ( 30 ) Dykhuizen , Antonie van Leeuwenhoek , 1998 , Kluwer Academic Publishers , vol. 73 , pp . 25 - 33. * Feb. 8 , 2013 (AU ) .. .. 2013900412 Foroumadi et . al ., European Journal ofMedicinal Chemistry , 2003 , Elsevier, vol. 38 , pp . 851 - 854 . * (51 ) Int. Ci. Lu -Lu et . al ., Infection and Immunity , 1992, American Society for A61K 31/ 352 (2006 .01 ) Microbiology , vol. 60 ( 9 ) , pp . 3807 - 3813 . * A61K 31 / 35 ( 2006 . 01 ) Akiyama et al ., Staphylococcus aureus infection on experimental A61K 31 /351 ( 2006 .01 ) croton oil - inflamed skin in mice . Staphylococcus aureus infection A61K 31 / 7048 ( 2006 . 01 ) on experimental croton oil - inflamed skin in mice . J . Dermatol . Sci . 8 ( 1 ) : 1 - 10 ( 1994 ) . A61K 9 / 06 ( 2006 . 01) Gilbert et al ., The 10x ' 20 Initiative : pursuing a global commitment A61K 9 / 00 ( 2006 . 01 ) to develop 10 new antibacterial drugs by 2020 . Clin . Infect . Dis. A61K 45 /06 ( 2006 .01 ) 50 ( 8 ) : 1081 - 3 (2010 ) . A61K 47 /06 ( 2006 .01 ) Guo et al. , In vivo bioluminescence imaging to evaluate systemic A61K 47 / 10 ( 2017 .01 ) and topical antibiotics against community -acquired methicillin resistant Staphylococcus aureus - infected skin wounds in mice . A61K 47 / 14 ( 2017 .01 ) Antimicrob . Agents Chemother . 57 ( 2 ) : 855 -63 ( 2013) . A61K 47 /44 ( 2017 .01 ) International Search Report and Written Opinion of the Interna A61L 15 / 46 ( 2006 .01 ) tional Searching Authority in connection with International Appli A61L 26 / 00 ( 2006 .01 ) cation No . PCT/ AU2014 /00101 , United States Patent Office , dated (52 ) U .S . CI. Feb . 10 , 2014 . CPC . .. .. .. .. A61K 31 /352 ( 2013 .01 ) ; A61K 9 / 0014 (Continued ) ( 2013 .01 ) ; A61K 9 /0017 ( 2013 .01 ) ; A61K 9 /0043 (2013 .01 ) ; A61K 9 /0046 (2013 .01 ) ; Primary Examiner — Sarah Pihonak A61K 9 / 0048 ( 2013 .01 ) ; A61K 9 / 06 ( 2013 .01 ) ; ( 74 ) Attorney , Agent, or Firm — Marshall , Gerstein & A61K 31/ 35 ( 2013 .01 ) ; A61K 31 /351 Borun LLP ( 2013 .01 ) ; A61K 31 / 7048 ( 2013 .01 ) ; A61K 45 / 06 ( 2013 .01 ) ; A61K 47 / 06 ( 2013 .01 ) ; A61K (57 ) ABSTRACT 47 / 10 ( 2013 .01 ) ; A61K 47 / 14 (2013 . 01 ) ; A6IK The invention is a method and composition for treating a 47 /44 (2013 .01 ) ; A61L 15 / 46 ( 2013 .01 ) ; A61L topical microbial infection in a subject . The method includes 26 /0066 ( 2013 .01 ) ; A6IL 2300/ 404 ( 2013 .01 ) the step of administering a therapeutically effective amount ( 58 ) Field of Classification Search of a polyether ionophore , or a therapeutically acceptable salt CPC .. .. A61K 31 /35 ; A61K 31 /351 ; A61K 31/ 352 ; thereof , to the subject . A61K 31 /7048 ; A61K 45 /06 ; A61K 9 / 0014 ; A61K 9 /0017 ; A61K 9 /0043 ; 12 Claims, 27 Drawing Sheets US 9 ,943 ,500 B2 Page 2 ( 56 ) References Cited OTHER PUBLICATIONS Kugelberg et al ., Establishment of a superficial skin infection model in mice by using Staphylococcus aureus and Streptococcus pyogenes . Antimicrob. Agents Chemother . 49 ( 8 ) : 3435 -41 (2005 ) . Liu , Microbial aspects of polyethers antibiotics: Activity, produc tion , and biosynthesis . Polyether Antibiotics Naturally Occurring Acid Ionophores vol. 1 : Biology . J . W . Westley , New York . Marcel Dekker Inc . 43 - 102 ( 1982 ) . McRipley et al. , Characterization and quantification of experimental surgical- wound infections used to evaluate topical antibacterial agents . Antimicrob . Agents Chemother . 10 ( 1 ) : 38 -44 ( 1976 ) . Naujokat et al . , Salinomycin as a drug for targeting human cancer stem cells . J . Biomed . Biotechnol . 2012 : 950658 ( 2012 ) . Stieritz et al. , A burned mouse model to evaluate anti -pseudomonas activity of topical agents. J . Antimicrob . Chemother . 9 ( 2 ) : 133 -40 ( 1982 ) . * cited by examiner atent Apr . 17 , 2018 Sheet 1 of 27 US 9 , 943 , 500 B2 Strain ID # Source Species Resistance Profile ATCC 49775 Human S . aureus MSS 1 Cow S . aureus MSS 2 Cat S . intermedius MSS 3 Cat S . aureus MSS 4 Unknown S . pseudintermedius MSS 5 Dog S . intermedius MSS 6 Human S . pseudintermedius MSS 7 Dog S . pseudintermedius P MSS 8 Dog Coagulase negative P , Te MSS 9 Dog S . intermedius MSS 10 Dog | S . intermedius MSS 11 Unknown Coagulase negative P , Te MSS 12 Dog S . pseudintermedius P MSS 13 Bird Coagulase negative P , Te MSS 14 Dog S . intermedius P MSS 15 Dog S . intermedius P , Te MSS 16 Pig Coagulase negative P | MSS 17 Pig S . aureus CI, E MSS 18 Dog S . intermedius P MSS 19 Dog Coagulase negative E MSS 20 Dog S . pseudintermedius CI, P , Te MRSA 1 Human S . aureus Enr , E , Gn , O , P . MRSA 2 Human S . aureus Gn , O , P , Tm MRSA 3 Human S . aureus E , Enr, O , P MRSA 4 . Human S . aureus E , Enr, O , P MRSA 5 Human | S . aureus E , Enr, Gn , O , P , Te MRSA 6 Human S . aureus E , Enr, O , P , Tm MRSA 7 Human S . aureus E , Enr, Gn , O , P , Tm MRSA 8 Human S . aureus E , Gn , O , P , Te , Tm MRSA 9 Human S . aureus E , O , P MRSA 10 Human S . aureus E , Enr, O , P MRSA 11 Human S . aureus 0 , P MRSA 12 Human S . aureus E , O , P , Te MRSA 13 Human S . aureus E , O , P MRSA 14 Human S . aureus E , O , P MRSA 15 Human S . aureus E , O , P MRSA 16 Human S . aureus O , P , Te FIGURE 1A atent Apr . 17 , 2018 Sheet 2 of 27 US 9 , 943 , 500 B2 Strain ID # Source Species | Resistance Profile MRSA 17 Human S . aureus E , Enr, Gn , O , P , Tm MRSA 18 Human S . aureus 10 , P , Tm MRSA 19 Human S . aureus E , O , P , Te , Tm MRSA 20 Human S . aureus Enr , O , P MR -CNS 1 Coagulase negative Enr, Gn , O , P , Tm Cl= clindamycin , Enr = enrofloxacin , E = erythromycin , Gn = gentamicin , O = oxacillin , P = penicillin G , Te = tetracycline , TmHLE = trimethoprim - sulfamethoxazole FIGURE 1B atent Apr . 17 , 2018 Sheet 3 of 27 US 9 , 943 , 500 B2 Negative Positive Control Control 0 , 25 871 ug ml JUIN stbinmenthow Tahan W 1 2 3 4 5 6 1 8 9 10 11 12 * * #in Simpurit" tek *WWW* tinit market *hátttt sehan * *** "EV guretat i NINY ETUSIN 4HFR* in Instrument Today! EX ini ih takich *** pulärtan 11 WHO it ta 20 1584 Nyhet! kelerinde * . 7 Herk heledag Widjeti Desting YERA *** * line * Test Cepounds * *** * *** .TUBE FD000000*** *** * Wir ora * * * *** " *** * WWWWWWW*** een Wow! ooooooooooooih * * * * * * * ** * * ** * * * * * * * * * * * * * * ** * * * * * * * * WWWWWWWWWWWWWWWWWW FIGURE 2 U. S . Patentatent Apr . 1717, , 2018 Sheet 4 of 27 US 9 , 943 , 500 B2 VC??? 128 ug /mL , Www *** arriver * *** w ti Figure 3 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ?????????????????????????????????????????????????????????????????????????? AYY Minimum Inhibitory concentrations . Meteo Sensitive (PusatiuogenudauogkjarayurXTILEIRA * sta Meto grains / / / / WW pics LA1068 124525 26315 LA9666 LTJESAntimicrobial Agent women who typiwwii w wwww Figure 4 atent Apr . 17 , 2018 Sheet 5 of 27 US 9 , 943 , 500 B2 Compound Ampicillin LP 1088 LP 1369 LP 4525 LP 6315 LP 9666 MIC50 0 0 . 5 2 MICMICO , 16 * . MC 0 . 25 - 32 0 . 5 - 4 0 . 5 - 2 0 , 25 - 1 2 - 8 2 – 128 Range Figure 5 Compound Ampicillin LP 1088 LP 1369 LP 1525 LP 6315 LP 9666 MIC50 128 1 * 05 32 NIC -> 128 1 6 MC 8 - 128 1 - 7 0 . 5 - 2 0 . 25 22 - 16 , 128 Range Figure 6 atent Apr . 17 , 2018 Sheet 6 of 27 US 9, 943, 500 B2 Minimum Bactericidal Concentration * MinimumBactericidalConcentrationwg/ml) Veiticillin -- Sensive straitis * Methicillin - - - çesistant cr. strains * LA1088 LP1369 LP4525 LP6315 LP9856 { { { { }{ Ex???à3???????? ?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? Figure 7 Compound LP 1088 LP 1369 LP 4525 LP 6315 LP 9666 { BC5k > >128 64 > 128 >> 128 > 128 MBC90 >> 128 > 128 > 128 > 128 > 128 MBC Range .4 - > 128 4 - > mat128 64 - > 128 64 - > 128 128 - > 128 Figure 8 atent Apr . 17 , 2018 Sheet 7 of 27 US 9 , 943 , 500 B2 Compound LP 1369 LP 4525 LP 6315 LP 9666 MBC30 > 128 > 128 > 128 DULODOU 128128 > 128 MBC > 128 > 128 >> 128 >> 128 >> 128 MBC Range 128 – > 128 64 - > 128 4 - > 128 4 - > 128 128 – > 128 Figure 9 Microdilution Time- Kill Assay (Strain : ATCC 49775) .
Load more

Recommended publications
  • List of New Drugs Approved in India from 1991 to 2000
    LIST OF NEW DRUGS APPROVED IN INDIA FROM 1991 TO 2000 S. No Name of Drug Pharmacological action/ Date of Indication Approval 1 Ciprofloxacin 0.3% w/v Eye Indicated in the treatment of February-1991 Drops/Eye Ointment/Ear Drop external ocular infection of the eye. 2 Diclofenac Sodium 1gm Gel March-1991 3 i)Cefaclor Monohydrate Antibiotic- In respiratory April-1991 250mg/500mg Capsule. infections, ENT infection, UT ii)Cefaclor Monohydrate infections, Skin and skin 125mg/5ml & 250mg/5ml structure infections. Suspension. iii)Cefaclor Monohydrate 100mg/ml Drops. iv)Cefaclor 187mg/5ml Suspension (For paediatric use). 4 Sheep Pox Vaccine (For April-1991 Veterinary) 5 Omeprazole 10mg/20mg Short term treatment of April-1991 Enteric Coated Granules duodenal ulcer, gastric ulcer, Capsule reflux oesophagitis, management of Zollinger- Ellison syndrome. 6 i)Nefopam Hydrochloride Non narcotic analgesic- Acute April-1991 30mg Tablet. and chronic pain, including ii)Nefopam Hydrochloride post-operative pain, dental 20mg/ml Injection. pain, musculo-skeletal pain, acute traumatic pain and cancer pain. 7 Buparvaquone 5% w/v Indicated in the treatment of April-1991 Solution for Injection (For bovine theileriosis. Veterinary) 8 i)Kitotifen Fumerate 1mg Anti asthmatic drug- Indicated May-1991 Tablet in prophylactic treatment of ii)Kitotifen Fumerate Syrup bronchial asthma, symptomatic iii)Ketotifen Fumerate Nasal improvement of allergic Drops conditions including rhinitis and conjunctivitis. 9 i)Pefloxacin Mesylate Antibacterial- In the treatment May-1991 Dihydrate 400mg Film Coated of severe infection in adults Tablet caused by sensitive ii)Pefloxacin Mesylate microorganism (gram -ve Dihydrate 400mg/5ml Injection pathogens and staphylococci). iii)Pefloxacin Mesylate Dihydrate 400mg I.V Bottles of 100ml/200ml 10 Ofloxacin 100mg/50ml & Indicated in RTI, UTI, May-1991 200mg/100ml vial Infusion gynaecological infection, skin/soft lesion infection.
    [Show full text]
  • A Review of Enrofloxacin for Veterinary Use Tessa Trouchon, Sebastien Lefebvre
    A Review of Enrofloxacin for Veterinary Use Tessa Trouchon, Sebastien Lefebvre To cite this version: Tessa Trouchon, Sebastien Lefebvre. A Review of Enrofloxacin for Veterinary Use. Open Journal of Veterinary Medicine, 2016, 6 (2), pp.40-58. 10.4236/ojvm.2016.62006. hal-01503397 HAL Id: hal-01503397 https://hal.archives-ouvertes.fr/hal-01503397 Submitted on 7 Apr 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - NoDerivatives| 4.0 International License Open Journal of Veterinary Medicine, 2016, 6, 40-58 Published Online February 2016 in SciRes. http://www.scirp.org/journal/ojvm http://dx.doi.org/10.4236/ojvm.2016.62006 A Review of Enrofloxacin for Veterinary Use Tessa Trouchon, Sébastien Lefebvre USC 1233 INRA-Vetagro Sup, Veterinary School of Lyon, Marcy l’Etoile, France Received 12 January 2016; accepted 21 February 2016; published 26 February 2016 Copyright © 2016 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract This review outlines the current knowledge on the use of enrofloxacin in veterinary medicine from biochemical mechanisms to the use in the field conditions and even resistance and ecotoxic- ity.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Infant Antibiotic Exposure Search EMBASE 1. Exp Antibiotic Agent/ 2
    Infant Antibiotic Exposure Search EMBASE 1. exp antibiotic agent/ 2. (Acedapsone or Alamethicin or Amdinocillin or Amdinocillin Pivoxil or Amikacin or Aminosalicylic Acid or Amoxicillin or Amoxicillin-Potassium Clavulanate Combination or Amphotericin B or Ampicillin or Anisomycin or Antimycin A or Arsphenamine or Aurodox or Azithromycin or Azlocillin or Aztreonam or Bacitracin or Bacteriocins or Bambermycins or beta-Lactams or Bongkrekic Acid or Brefeldin A or Butirosin Sulfate or Calcimycin or Candicidin or Capreomycin or Carbenicillin or Carfecillin or Cefaclor or Cefadroxil or Cefamandole or Cefatrizine or Cefazolin or Cefixime or Cefmenoxime or Cefmetazole or Cefonicid or Cefoperazone or Cefotaxime or Cefotetan or Cefotiam or Cefoxitin or Cefsulodin or Ceftazidime or Ceftizoxime or Ceftriaxone or Cefuroxime or Cephacetrile or Cephalexin or Cephaloglycin or Cephaloridine or Cephalosporins or Cephalothin or Cephamycins or Cephapirin or Cephradine or Chloramphenicol or Chlortetracycline or Ciprofloxacin or Citrinin or Clarithromycin or Clavulanic Acid or Clavulanic Acids or clindamycin or Clofazimine or Cloxacillin or Colistin or Cyclacillin or Cycloserine or Dactinomycin or Dapsone or Daptomycin or Demeclocycline or Diarylquinolines or Dibekacin or Dicloxacillin or Dihydrostreptomycin Sulfate or Diketopiperazines or Distamycins or Doxycycline or Echinomycin or Edeine or Enoxacin or Enviomycin or Erythromycin or Erythromycin Estolate or Erythromycin Ethylsuccinate or Ethambutol or Ethionamide or Filipin or Floxacillin or Fluoroquinolones
    [Show full text]
  • An Investigation of Class 1 Integrons and Integrase Gene In
    AN INVESTIGATION OF CLASS 1 INTEGRONS AND INTEGRASE GENE IN ESCHERICHIA COLI AND MANNHEIMIA HAEMOLYTICA FROM BEEF CATTLE IN WESTERN CANADA A Thesis Presented to The Faculty of Graduate Studies of The University of Guelph by MATTHEW LESLIE In partial fulfillment of requirements for the degree of Master of Science May, 2011 © Matthew Leslie, 2011 Library and Archives Bibliotheque et 1*1 Canada Archives Canada Published Heritage Direction du Branch Patrimoine de I'edition 395 Wellington Street 395, rue Wellington OttawaONK1A0N4 Ottawa ON K1A 0N4 Canada Canada Your file Vote reference ISBN: 978-0-494-82791-8 Our We Notre r6f6rence ISBN: 978-0-494-82791-8 NOTICE: AVIS: The author has granted a non­ L'auteur a accorde une licence non exclusive exclusive license allowing Library and permettant a la Bibliotheque et Archives Archives Canada to reproduce, Canada de reproduire, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par telecommunication ou par I'lnternet, preter, telecommunication or on the Internet, distribuer et vendre des theses partout dans le loan, distribute and sell theses monde, a des fins commerciaies ou autres, sur worldwide, for commercial or non­ support microforme, papier, electronique et/ou commercial purposes, in microform, autres formats. paper, electronic and/or any other formats. The author retains copyright L'auteur conserve la propriete du droit d'auteur ownership and moral rights in this et des droits moraux qui protege cette these. Ni thesis. Neither the thesis nor la these ni des extraits substantiels de celle-ci substantial extracts from it may be ne doivent etre imprimes ou autrement printed or otherwise reproduced reproduits sans son autorisation.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Summary of Product Characteristics
    Revised: March 2021 AN: 01885/2020 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cepravin Dry Cow 250mg Intramammary suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Constituent: per syringe Cefalonium 0.250 g (as cefalonium dihydrate) For a full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Intramammary suspension 4. CLINICAL PARTICULARS 4.1 Target species Cattle 4.2 Indications for use, specifying the target species Recommended for routine dry cow therapy to treat existing sub-clinical infections and to prevent new infections which occur during the dry period. 4.3 Contraindications Not for use in the lactating cow. Not intended for use within 54 days of calving. 4.4 Special Warnings: No special warnings are considered necessary. 4.5 Special precautions for use i. Special precautions for use in animals Use of the product should be based on susceptibility testing of the bacteria isolated from milk samples from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria. Page 1 of 8 Revised: March 2021 AN: 01885/2020 Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to cefalonium and may decrease the effectiveness of treatment with other beta lactams. Dry cow therapy protocols should take local and national policies on antimicrobial use into consideration, and undergo regular veterinary review. The feeding to calves of milk containing residues of cefalonium that could select for antimicrobial-resistant bacteria (e.g. production of beta-lactamases) should be avoided up to the end of the milk withdrawal period, except during the colostral phase.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Multiplex De Novo Sequencing of Peptide Antibiotics
    JOURNAL OF COMPUTATIONAL BIOLOGY Volume 18, Number 11, 2011 Research Articles # Mary Ann Liebert, Inc. Pp. 1371–1381 DOI: 10.1089/cmb.2011.0158 Multiplex De Novo Sequencing of Peptide Antibiotics HOSEIN MOHIMANI,1 WEI-TING LIU,2 YU-LIANG YANG,3 SUSANA P. GAUDEˆ NCIO,4 WILLIAM FENICAL,4 PIETER C. DORRESTEIN,2,3 and PAVEL A. PEVZNER5 ABSTRACT Proliferation of drug-resistant diseases raises the challenge of searching for new, more efficient antibiotics. Currently, some of the most effective antibiotics (i.e., Vancomycin and Daptomycin) are cyclic peptides produced by non-ribosomal biosynthetic pathways. The isolation and sequencing of cyclic peptide antibiotics, unlike the same activity with linear peptides, is time-consuming and error-prone. The dominant technique for sequencing cyclic peptides is nuclear magnetic resonance (NMR)–based and requires large amounts (milli- grams) of purified materials that, for most compounds, are not possible to obtain. Given these facts, there is a need for new tools to sequence cyclic non-ribosomal peptides (NRPs) using picograms of material. Since nearly all cyclic NRPs are produced along with related analogs, we develop a mass spectrometry approach for sequencing all related peptides at once (in contrast to the existing approach that analyzes individual peptides). Our results suggest that instead of attempting to isolate and NMR-sequence the most abundant com- pound, one should acquire spectra of many related compounds and sequence all of them simultaneously using tandem mass spectrometry. We illustrate applications of this approach by sequencing new variants of cyclic peptide antibiotics from Bacillus brevis, as well as sequencing a previously unknown family of cyclic NRPs produced by marine bacteria.
    [Show full text]
  • (OTC) Antibiotics in the European Union and Norway, 2012
    Perspective Analysis of licensed over-the-counter (OTC) antibiotics in the European Union and Norway, 2012 L Both 1 , R Botgros 2 , M Cavaleri 2 1. Public Health England (PHE), London, United Kingdom 2. Anti-infectives and Vaccines Office, European Medicines Agency (EMA), London, United Kingdom Correspondence: Marco Cavaleri ([email protected]) Citation style for this article: Both L, Botgros R, Cavaleri M. Analysis of licensed over-the-counter (OTC) antibiotics in the European Union and Norway, 2012. Euro Surveill. 2015;20(34):pii=30002. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2015.20.34.30002 Article submitted on 16 September 2014 / accepted on 09 February 2015 / published on 27 August 2015 Antimicrobial resistance is recognised as a growing throughout the EU; however, there are still consider- problem that seriously threatens public health and able differences in Europe due to the different health- requires prompt action. Concerns have therefore been care structures and policies (including the extent of raised about the potential harmful effects of making pharmacist supervision for OTC medicines), reimburse- antibiotics available without prescription. Because of ment policies, and cultural differences of each Member the very serious concerns regarding further spread of State. Therefore, the availability of OTC medicines var- resistance, the over-the-counter (OTC) availability of ies in the EU and products sold as POM in certain coun- antibiotics was analysed here. Topical and systemic tries can be obtained as OTC medicines in others. OTC antibiotics and their indications were determined across 26 European Union (EU) countries and Norway As risk minimisation is an important criterion for some by means of a European survey.
    [Show full text]
  • Cukurova Medical Journal Mania Associated with Cycloserine
    Cukurova Medical Journal Cukurova Med J 2016;41(Suppl 1):79-81 ÇUKUROVA ÜNİVERSİTESİ TIP FAKÜLTESİ DERGİSİ DOI: 10.17826/cutf.254643 OLGU SUNUMU/CASE REPORT Mania associated with cycloserine Sikloserin ile ilişkili mani Soner Çakmak1, Ufuk Bal2, Volkan Gelegen1, Gonca Karakuş1, Lut Tamam1 1Cukurova University Faculty of Medicine, Department of Psychiatry, Adana, Turkey 2Dr. Aşkım Tüfekçi State Hospital, Department of Psychiatry, Adana, Turkey Cukurova Medical Journal 2016;41(Suppl 1):79-81. Abstract Öz Cycloserine is a broad spectrum antibiotic agent Sikloserin, çoklu ilaç direnci olan akciğer ve akciğer dışı commonly used as a second-line treatment for patients tüberkülozlarda ikinci basamak tedavide sık kullanılan with multi-drug resistant pulmonary and extrapulmonary geniş spektrumlu bir antibiyotik ajandır. Birçok tuberculosis and associated with many neuropsychiatric nöropsikiyatrik yan etki ile ilişkilendirilmektedir. Yan adverse events. Mania is rarely reported in this context. etkileri arasında nadir olmakla birlikte mani ile We report a case of 38-year-old male diagnosed as Pott ilişkilendirilen olgular da bulunmaktadır. Bu olguya Pott disease and developed manic symptoms while on second hastalığı tanısı konulmuş ve çoklu ilaç direnci olan akciğer line anti-tubercular treatment for multi-drug resistant ve akciğer dışı tüberküloz olarak tanımlanmış, tedavisinde pulmonary and extrapulmonary tuberculosis. We related sikloserin kullanılmış olan 38 yaşında bir erkek hasta these manic symptoms with cycloserine. The patient tartışılmıştır. Tedavi sürecinde mani gelişmiş ve sikloserin remitted significantly in one week period after ile ilişkili olabileceği düşünülmüştür. Mani bulguları ilacın discontinuation of cycloserine and initiation of kesilmesi ve antipsikotik medikasyonla 1 haftalık süreçte antipsychotic treatment. This case emphasizes that manic gerilemiştir.
    [Show full text]